Navigation Links
Pfizer Wins CIO 100 Award for Patient Enrollment Optimization Solution From DecisionView
Date:7/27/2010

SAN FRANCISCO, July 27 /PRNewswire/ -- DecisionView Inc., a leading provider of software solutions to optimize clinical trial enrollment for life sciences companies, is pleased to announce that Pfizer has won a CIO 100 award based on their successful deployment of DecisionView StudyOptimizer (see award details here: http://www.cio.com/cio100/detail/2072). StudyOptimizer is a web-based patient enrollment optimization solution that automates the planning and tracking of patient enrollment for global clinical trials. It leverages predictive modeling to forecast enrollment end dates during planning, throughout execution and for modeling recovery scenarios when enrollment goes off track.

Pfizer Clinical Trial Enrollment Optimization

The CIO 100 2010 Winner Profile describes Pfizer's clinical trial enrollment optimization project this way:

"To help complete their clinical trials on time and on budget, Pfizer deployed DecisionView's StudyOptimizer, enabling clinical teams to optimize enrollment in trials using predictive modeling and visualization. The Software-as-a-Service (SaaS)-based system allows users to analyze current data, forecast trial end-dates, and track the impact of possible course changes. Among its benefits, the system has reduced the time it takes to enroll patients by 30 to 40 days, saving $4 million annually."

CIO 100 Award Criteria

The 2010 CIO 100 Awards, sponsored by CIO magazine, honor 100 companies that are creating new business value by innovating with technology. The judges evaluated the applications according to two criteria: innovation and business value. CIO 100 winners had to demonstrate that they not only were able to create new value using IT and executed their project well, but also did so in uncommon, innovative ways:

  • pioneering a new technology,
  • applying a familiar technology to a new purpose,
  • setting the bar higher for their competitors.

ABOUT DECISIONVIEW

DecisionView develops innovative web-based software solutions that enable life sciences organizations around the world to improve clinical trial performance. DecisionView's flagship solution, StudyOptimizer, helps organizations optimize clinical trial enrollment by aggregating patient recruitment data from multiple sources and providing analytics, visualizations, and predictive scenario modeling that delivers unique and actionable insight. StudyOptimizer is used by four of the top ten global pharmaceutical companies, and has been used on over 750 clinical studies with over 120,000 subjects enrolled in over ten different therapeutic areas. Primary investors in the company include Granite Ventures and Aeris Capital. For additional information about DecisionView, go to www.decisionview.com or call 415-538-1800.


'/>"/>
SOURCE DecisionView Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Pfizer Announces EMPHASIS-HF Trial to Halt Recruitment due to Significant Benefit Observed in Patients Treated With Inspra® (Eplerenone)
2. Pfizer Animal Health Expands Global Commitment to a Safe Food Supply with a New Focus on Healthy Fish
3. Oramed Pharmaceuticals Announces That Dr. Michael Berelowitz, Senior Vice President at Pfizer, Joins its Board of Directors
4. Pfizer Global Manufacturing Announces Plans to Reconfigure Its Global Plant Network
5. Anavex comments on failure of Pfizer and Medivations Alzheimers investigational drug Dimebon during Phase 3 clinical trials
6. Wyeth Announces Stockholder Approval of Pfizer Merger at 2009 Annual Meeting
7. Pfizer Global R&D Presents 2008 Top Intermediates CMO Award to Asymchem
8. GSK and Pfizer Innovative Agreement Creates Specialist HIV Company
9. Lakewood-Amedex, Inc. Appoints William J. Robison, Former Executive Vice President of Pfizer, as Board Member
10. MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant
11. JMAR Technologies' Chief Scientist Invited by Pfizer Inc. to Speak at IFPAC -- BioSentry Makes Strides in Pharma Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 01, 2016 , ... ... findings demonstrating the value of DNA microarray comparative genomic hybridization (array CGH) ... Antonio Breast Cancer Symposium. Using molecular test results from tumors with previously ...
(Date:12/2/2016)... , ... December 01, 2016 , ... The Conference Forum ... to three days and will take place on February 1-3, 2017 at the Roosevelt ... James Gulley (NCI), the program provides a unique 360-degree approach, which addresses the most ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... dedicated to collaboratively developing improved chemistry, manufacturing and control technologies for the ... UHPLC, with robust, probe-based sampling. , Online liquid chromatography analysis is ...
(Date:12/2/2016)... The immunohistochemistry (IHC) market is projected to reach ... during the forecast period of 2016 to 2021 dominated by immunohistochemistry ... the largest share of immunohistochemistry (IHC) market, by end user.   ... , , ... across 225 pages, profiling 10 companies and supported with 181 tables ...
Breaking Biology Technology:
(Date:6/27/2016)... 2016 Research and Markets has announced the ... report to their offering. The ... to grow at a CAGR of 12.28% during the period ... an in-depth market analysis with inputs from industry experts. The report ... years. The report also includes a discussion of the key vendors ...
(Date:6/21/2016)... , June 21, 2016 NuData Security announced ... new role of principal product architect and that ... director of customer development. Both will report directly ... officer. The moves reflect NuData,s strategic growth in ... to high customer demand and customer focus values. ...
(Date:6/9/2016)... , June 9, 2016  Perkotek an innovation leader in attendance control systems ... seamlessly log work hours, for employers to make sure the right employees are actually ... http://photos.prnewswire.com/prnh/20160609/377486LOGO ... ... ...
Breaking Biology News(10 mins):